News

Hit by rising medical care costs and squeezed by government changes, the health care conglomerate acknowledges “pricing and operational mistakes” affected its bottom line and has outlined steps to ...
Investing.com - Novo Nordisk (NYSE:NVO)’s weight-loss and diabetes drugs Wegovy and Ozempic could face increased pressure in the future, weighing on the Danish pharmaceutical group’s earnings, ...
Shares in Asia are mostly higher after the U.S. and China ended their latest round of trade talks without a deal. U.S, ...
Novo Nordisk fell by 21.83 percent on Tuesday to end at $53.94 apiece as investors unloaded positions following the company’s ...
The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...
China trade talks wrap up, Berkshire’s potential railroad deal, oil prices spike, and more news to start your day.
CNBC's Karen Gilchrist discusses Novo Nordisk's new CEO and the pharma giant's move to cut its full-year guidance on weaker ...
Novo Nordisk ( NVO) continued its downward spiral and fell 3.8% in premarket trade, a day after the Danish drugmaker slashed ...
Wall Street had a relatively muted reaction after China’s top trade official said in Stockholm that China and the United ...